skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

US_Shutdown_Pharma

 

Another ANDA bolus is coming, although not because of a new US FDA policy or assessment time change.

If generic drug sponsors adhere to historical averages, the total number of applications processed upon the end of the government shutdown could be among the largest in a single month of the GDUFA era. Applications received in December 2018 and January and February 2019 could total 300 or more, based on a Pink Sheet analysis of historical ANDA submission figures. (See chart below.)

Since the shutdown began, FDA has not been allowed to accept applications that require a fiscal year 2019 user fee payment, which includes ANDAs.

Many already may be sitting in FDA's electronic gateway, but will not be officially received until after the shutdown ends, meaning assessment staff cannot begin working on them. The result is a growing pot of applications that will reach the agency all at once, pressuring assessment staff when they return to work.

December typically is among the busiest months of the year for ANDA submissions, as companies work to close out their generic drug portfolios before the end of the calendar year. Sponsors have submitted on average about 163 ANDAs in December since the generic drug user fee program launched in October 2012.

January and February tend to see lighter submission volume, in part because of the December rush. Sponsors have sent the agency about 60 ANDAs in January and another 55 in February on average.

The combined average of about 278 ANDAs would be the second-largest bolus received in a single month in the GDUFA era, although it may be divided between pre- and post-shutdown receipts. FDA received ANDAs for three weeks in December, but has not yet reported that figure. The dates sponsors sent ANDAs that month would affect the number awaiting assessment.

The combined bolus also may be much higher than the three-month average. Submission totals during fiscal year 2015 were down substantially after sponsors submitted 635 applications in June 2014 to avoid new stability requirements about to go into effect. (Also see "ANDA Avalanche: How Will FDA Deal With The 600 Received This Month?" - Pink Sheet, 30 Jun, 2014.)

If FY 2015 figures are disregarded as outliers, the submission average for the December to February period jumps to more than 313.

Robert Pollock, senior adviser and outside director to the board at Lachman Consultants, told the Pink Sheet that in his opinion (not based on information from FDA) a 300-plus ANDA bolus is possible. Pollock said many December ANDAs tend to be submitted near the end of the month, meaning they could have arrived after the shutdown began.

The March Bolus Also Is Approaching

If the shutdown lingers through February, the bolus also could merge with the traditional March rush, further escalating the pressure on the agency.

The March average submission total is about 118. Spikes tend to occur then as Indian generics firms send submissions before closing out their fiscal year. (Also see "Generic Drug Puzzle: Why Did ANDA Submissions Spike Again?" - Pink Sheet, 11 Apr, 2017.)

Overall, ANDA submissions tend to follow a yo-yo pattern – a busy month is followed by several down months. (See chart below.)

December 2016 now stands as the second-highest total, when 235 ANDAs were submitted. FDA had recently implemented its 10-month ANDA assessment goal, which may have helped increase the volume. (Also see "ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System" - Pink Sheet, 9 Jan, 2017.)

Sponsors submitted 216 ANDAs in September 2017 in part to avoid paying a substantially higher user fee when the new fiscal year started the next month. (Also see "There's The Bolus! ANDA Sponsors Race To Avoid User Fee Spike" - Pink Sheet, 9 Oct, 2017.)

Will Shutdown Bolus Affect Assessment Goals?

The shutdown bolus will serve as a big stress test for FDA's Office of Generic Drugs and its ability to meet its assessment goals.

All the applications filed during the shutdown may receive the same filing date for administrative purposes, which could spark clashes if that leads to shared 180-day exclusivity awards. (Also see "US Federal Courts Can Operate Until Jan. 25; Patent Office Faces Eminent Closure Under Shutdown" - Pink Sheet, 16 Jan, 2019.)

Some likely will not clear the initial filing assessment, but OGD still may be assessing hundreds of ANDAs with 10-month assessment goals about the same time.

Pollock said OGD has never seen this many ANDAs with similar goals since the program launched. He predicted a "wild ride" in a blog post on the subject.

"They have not had a huge single submission month with the 10-month review clock," he said in an email to the Pink Sheet. "I believe it will certainly put a strain on the program to be able to meet all of the GDUFA review goals if the number is well north of 200 [submissions]."

The Association for Accessible Medicines, a generic drug trade association, told the Pink Sheet that it does not see the upcoming submissions bolus and subsequent review goals as an issue "at this point in time" and said special measures to handle it are not a consideration.

FDA responded that it had no information to share.

Indeed, no special measures were implemented to handle the June 2014 bolus, but those applications also were not subject to formal review goals under GDUFA.

At the same time, OGD Director Kathleen Uhl is expected to retire in February, meaning the staff will be adjusting to a new permanent or acting director. (Also see "US FDA Generic Drug Office Director Uhl Announces Retirement" - Pink Sheet, 17 Jul, 2018.)

FDA's generics staff continues to work during the shutdown, but only on applications that were already in-house when the so-called "lapse period" began or do not require a user fee payment. They are supported by carryover user fee revenue, which FDA says will last for several more months. (Also see "US FDA Shuttering More Operations As User Fee Money Dwindles" - Pink Sheet, 23 Jan, 2019.)

The agency now is approving more ANDAs per day during the shutdown than in the three weeks preceding it in December. (Also see "Shutdown Week Four: FDA Maintains Pre-Shutdown Output Pace In Some Cases" - Pink Sheet, 14 Jan, 2019.)

 

おすすめのニュース&レポート

  • Pink Sheet: 世界の薬事規制と承認審査に関するニュース

    Cancer Immunotherapy: When To Stop Treatment Remains Unanswered Question

    02 Aug 2017

    Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.

    Topics Clinical trials

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース, Pink Sheet: 世界の薬事規制と承認審査に関するニ...

    医療用医薬品、医療機器、薬事規制ニュース

    インフォーマ・ファーマインテリジェンスでは、医薬品とバイオテック及び医療機器を含む世界のヘルスケア産業全般に関するニュースを配信しています。65名のジャーナリストと300名超のアナリストが、独立した立場と分析でグローバル化した今日の医薬品産業のニュースをお伝えします。

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Novartis Pharma CEO Sees Zolgensma Supplanting Spinraza

    The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.

    Topics Business strategies Drug approval Drug development landscape Drug review

;

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。